DDInter90 DDInter1676
Amprenavir is a protease inhibitor used to treat HIV infection.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Amprenavir {u} (Compound) resembles {v} (Compound) Darunavir
Amprenavir {u} (Compound) resembles {v} (Compound) Fosamprenavir
Amprenavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Amprenavir {u} (Compound) binds {v} (Gene) ABCB1
Amprenavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Amprenavir {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Amprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zafirlukast
Amprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludrocortisone
Amprenavir (Compound) resembles Darunavir (Compound)
Amprenavir (Compound) resembles Fosamprenavir (Compound)
Amprenavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Amprenavir (Compound) binds ABCB1 (Gene)
Amprenavir (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Amprenavir (Compound) causes Musculoskeletal discomfort (Side Effect)
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone